620 related articles for article (PubMed ID: 17375303)
1. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel.
Ho EA; Vassileva V; Allen C; Piquette-Miller M
J Control Release; 2005 May; 104(1):181-91. PubMed ID: 15866344
[TBL] [Abstract][Full Text] [Related]
3. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors.
Ho EA; Soo PL; Allen C; Piquette-Miller M
J Control Release; 2007 Jan; 117(1):20-7. PubMed ID: 17113177
[TBL] [Abstract][Full Text] [Related]
4. Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.
Danhier F; Magotteaux N; Ucakar B; Lecouturier N; Brewster M; Préat V
Eur J Pharm Biopharm; 2009 Oct; 73(2):230-8. PubMed ID: 19577643
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.
Zhang C; Qu G; Sun Y; Wu X; Yao Z; Guo Q; Ding Q; Yuan S; Shen Z; Ping Q; Zhou H
Biomaterials; 2008 Mar; 29(9):1233-41. PubMed ID: 18093646
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and characterization of low-toxic amphiphilic chitosan derivatives and their application as micelle carrier for antitumor drug.
Huo M; Zhang Y; Zhou J; Zou A; Yu D; Wu Y; Li J; Li H
Int J Pharm; 2010 Jul; 394(1-2):162-73. PubMed ID: 20457237
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor.
Sheihet L; Garbuzenko OB; Bushman J; Gounder MK; Minko T; Kohn J
Eur J Pharm Sci; 2012 Feb; 45(3):320-9. PubMed ID: 22155544
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
Liu X; Sun J; Chen X; Wang S; Scott H; Zhang X; Zhang Q
J Pharm Pharmacol; 2012 Jun; 64(6):775-82. PubMed ID: 22571255
[TBL] [Abstract][Full Text] [Related]
9. Porous quaternized chitosan nanoparticles containing paclitaxel nanocrystals improved therapeutic efficacy in non-small-cell lung cancer after oral administration.
Lv PP; Wei W; Yue H; Yang TY; Wang LY; Ma GH
Biomacromolecules; 2011 Dec; 12(12):4230-9. PubMed ID: 22044456
[TBL] [Abstract][Full Text] [Related]
10. Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel.
Kim JH; Kim YS; Kim S; Park JH; Kim K; Choi K; Chung H; Jeong SY; Park RW; Kim IS; Kwon IC
J Control Release; 2006 Mar; 111(1-2):228-34. PubMed ID: 16458988
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable nanoparticles based on linoleic acid and poly(beta-malic acid) double grafted chitosan derivatives as carriers of anticancer drugs.
Zhao Z; He M; Yin L; Bao J; Shi L; Wang B; Tang C; Yin C
Biomacromolecules; 2009 Mar; 10(3):565-72. PubMed ID: 19175304
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
Danhier F; Lecouturier N; Vroman B; Jérôme C; Marchand-Brynaert J; Feron O; Préat V
J Control Release; 2009 Jan; 133(1):11-7. PubMed ID: 18950666
[TBL] [Abstract][Full Text] [Related]
13. Enhanced efficacy of a novel controlled release paclitaxel formulation (PACLIMER delivery system) for local-regional therapy of lung cancer tumor nodules in mice.
Harper E; Dang W; Lapidus RG; Garver RI
Clin Cancer Res; 1999 Dec; 5(12):4242-8. PubMed ID: 10632366
[TBL] [Abstract][Full Text] [Related]
14. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery.
Soga O; van Nostrum CF; Fens M; Rijcken CJ; Schiffelers RM; Storm G; Hennink WE
J Control Release; 2005 Mar; 103(2):341-53. PubMed ID: 15763618
[TBL] [Abstract][Full Text] [Related]
15. Drug release mechanism of paclitaxel from a chitosan-lipid implant system: effect of swelling, degradation and morphology.
Lim Soo P; Cho J; Grant J; Ho E; Piquette-Miller M; Allen C
Eur J Pharm Biopharm; 2008 May; 69(1):149-57. PubMed ID: 18164931
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
Armstrong DK; Fleming GF; Markman M; Bailey HH
Gynecol Oncol; 2006 Nov; 103(2):391-6. PubMed ID: 16626792
[TBL] [Abstract][Full Text] [Related]
17. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
Gelderblom H; Verweij J; van Zomeren DM; Buijs D; Ouwens L; Nooter K; Stoter G; Sparreboom A
Clin Cancer Res; 2002 Apr; 8(4):1237-41. PubMed ID: 11948138
[TBL] [Abstract][Full Text] [Related]
18. Hydrotropic oligomer-conjugated glycol chitosan as a carrier of paclitaxel: synthesis, characterization, and in vivo biodistribution.
Saravanakumar G; Min KH; Min DS; Kim AY; Lee CM; Cho YW; Lee SC; Kim K; Jeong SY; Park K; Park JH; Kwon IC
J Control Release; 2009 Dec; 140(3):210-7. PubMed ID: 19560497
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of an MPC-BMA co-polymer as a nanotransporter for paclitaxel.
Wada M; Jinno H; Ueda M; Ikeda T; Kitajima M; Konno T; Watanabe J; Ishihara K
Anticancer Res; 2007; 27(3B):1431-5. PubMed ID: 17595758
[TBL] [Abstract][Full Text] [Related]
20. [Solubilizing and sustained-releasing abilities and safety preliminary evaluation for paclitaxel based on N-octyl-O, N-carboxymethyl chitosan polymeric micelles].
Huo MR; Zhang Y; Zhou JP; Lü L; Liu H; Liu FJ
Yao Xue Xue Bao; 2008 Aug; 43(8):855-61. PubMed ID: 18956780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
